World's Best Scientists 2026 revealed!
Antoine Italiano

Antoine Italiano

D-Index & Metrics

Medicine

D-Index
83
Citations
32681
World Ranking
15424
National Ranking
499

Overview

Antoine Italiano is affiliated with the University of Bordeaux in France. Their research spans across multiple fields including Medicine and Biochemistry, Genetics and Molecular Biology, with a strong emphasis on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Cancer Research, and Immunology.

The main topics covered in their research include:

  • Sarcoma Diagnosis and Treatment
  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • Lung Cancer Treatments and Mutations
  • CAR-T cell therapy research
  • Colorectal Cancer Treatments and Studies
  • Vascular Tumors and Angiosarcomas

Antoine Italiano has contributed to a range of recent publications, some of which are:

  • Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study (2020), published in The Lancet Oncology
  • B cells are associated with survival and immunotherapy response in sarcoma (2020), published in Nature
  • Sotorasib for Lung Cancers with KRAS p.G12C Mutation (2021), published in New England Journal of Medicine
  • B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome (2022), published in Nature Reviews Clinical Oncology
  • ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group (2022), published in Annals of Oncology

The scientist frequently publishes in several notable venues, including:

  • Annals of Oncology (79 publications)
  • Journal of Clinical Oncology (79 publications)
  • Cancer Research (74 publications)
  • Clinical Cancer Research (19 publications)
  • European Journal of Cancer (19 publications)

Collaborative work is a significant aspect of Antoine Italiano's research output. Frequent co-authors include:

  • Jean-Yves Blay (103 joint works)
  • Alban Bessede (65 joint works)
  • Maud Toulmonde (62 joint works)
  • Sophie Cousin (61 joint works)
  • François Le Loarer (61 joint works)

Best Publications

  • Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.

    Aurélien Marabelle;Marwan Fakih;Juanita Lopez;Manisha Shah

  • Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

    David M. Hyman;Igor Puzanov;Vivek Subbiah;Jason E. Faris

  • B cells are associated with survival and immunotherapy response in sarcoma.

    Florent Petitprez;Aurélien de Reyniès;Emily Z. Keung;Tom Wei Wu Chen

  • Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy

    Carola H. Ries;Michael A. Cannarile;Sabine Hoves;Jörg Benz

  • Sotorasib for Lung Cancers with KRAS p.G12C Mutation.

    Ferdinandos Skoulidis;Bob T. Li;Grace K. Dy;Timothy J. Price

  • Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study.

    Hyun Cheol Chung;Willeke Ros;Jean Pierre Delord;Ruth Perets

  • Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

    Patrick Schöffski;Sant Chawla;Robert G. Maki;Antoine Italiano

  • Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.

    Isabelle Ray-Coquard;Jean-Yves Blay;Antoine Italiano;Axel Le Cesne

  • Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

    Antoine Italiano;Jean-Charles Soria;Maud Toulmonde;Jean-Marie Michot

  • Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression

    Lucile Vanhersecke;Maxime Brunet;Jean-Philippe Guégan;Christophe Rey

  • CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study

    Philippe A Cassier;Antoine Italiano;Carlos A Gomez-Roca;Christophe Le Tourneau

  • Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.

    Vivek Subbiah;Ulrik Lassen;Elena Élez;Antoine Italiano

  • Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial.

    Maud Toulmonde;Nicolas Penel;Julien Adam;Julien Adam;Christine Chevreau

  • Efficacy and Safety of Pembrolizumab for the Treatment of Advanced Biliary Cancer: Results From the KEYNOTE-158 and KEYNOTE-028 Studies

    Sarina A. Piha-Paul;Do Youn Oh;Makoto Ueno;David Malka

  • Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.

    Susan M. Domchek;Sophie Postel-Vinay;Sophie Postel-Vinay;Sophie Postel-Vinay;Seock Ah Im;Yeon Hee Park

  • Trends in survival for patients with metastatic soft-tissue sarcoma†

    Antoine Italiano;Simone Mathoulin-Pelissier;Axel Le Cesne;Philippe Terrier

  • Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.

    Florence Duffaud;Olivier Mir;Pascaline Boudou-Rouquette;Sophie Piperno-Neumann

  • Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.

    Mrinal Gounder;Patrick Schöffski;Robin L. Jones;Mark Agulnik

  • Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial

    Olivier Mir;Thomas Brodowicz;Antoine Italiano;Jennifer Wallet

  • Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis

    Philippe A. Cassier;Hans Gelderblom;Silvia Stacchiotti;David Thomas

Frequent Co-Authors

Jean-Yves Blay
Jean-Yves Blay Claude Bernard University Lyon 1
Christine Chevreau
Christine Chevreau DuPont (United States)
Axel Le Cesne
Axel Le Cesne Institut Gustave Roussy
François Bertucci
François Bertucci Aix-Marseille University
Isabelle Ray-Coquard
Isabelle Ray-Coquard Claude Bernard University Lyon 1
Jean-Michel Coindre
Jean-Michel Coindre University of Bordeaux
Robert G. Maki
Robert G. Maki University of Pennsylvania
Hans Gelderblom
Hans Gelderblom Leiden University Medical Center
Silvia Stacchiotti
Silvia Stacchiotti University of Milan
Alessandro Gronchi
Alessandro Gronchi University of Milan

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative and supplementary healthcare degrees can broaden your career options within the medical field. Online learning makes it easier than ever to access top-rated programs wherever you are based.

For those interested in advanced pharmacy roles, a 3 year online pharmd program is a flexible pathway, offering rigorous training from home for those pursuing pharmacy licensure. Alternatively, if you are passionate about health data and technology, an online mhi (Master’s in Health Information Management) opens doors to leadership in medical records and informatics.

There are also high-demand, entry-level roles available. Those seeking quick certification can consider the cheapest medical billing and coding online courses to build skills in administrative healthcare operations.

For those who want to advance nursing careers without commuting or relocating, many colleges now offer affordable online fnp programs for becoming a Family Nurse Practitioner.

Whether you are changing focus or seeking advancement, these online options offer flexibility, affordability, and wide-ranging career potential in healthcare.

Best Scientists Citing Antoine Italiano

Trending Scientists